Dubai, UAE – The Emirates Pharmaceutical Foundation confirmed that issuing regulatory approval for the drug “Itvisma” represents a pivotal step that reflects the country’s commitment to providing the latest advanced gene therapies to patients.
Especially those with rare genetic diseases such as spinal muscular atrophy.
It also embodies the efficiency of the UAE’s health system and its ability to evaluate and approve innovative medicines according to the highest scientific standards and within effective timeframes.
Ensuring that patients have rapid access to leading treatment options that enhance their quality of life.
The Emirates Pharmaceutical Foundation announced the approval of the drug “Itvisma”.
It is a gene therapy based on an adenoviral vector, used to treat spinal muscular atrophy in medically qualified adults and children aged two years and older.
With this decision, the UAE becomes the second country in the world to grant approval for this treatment.
This strengthens its leadership in accelerating the arrival of advanced medical innovations to patients in the region.
The regulatory approval for Itvisma reflects the Emirates Drug Corporation’s strategy aimed at strengthening the country’s position as a regional center for pharmaceutical innovation.
By providing advanced genetic therapies of the highest quality and safety, the organization employs a modern regulatory model based on careful governance.
In addition to transparency and global partnerships, to support research and development, adoption of the latest technologies, and integrated care.
